anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
Il: \sn\Interwovn\NRPortbl\DCC\SXN\15181335_l.docx- 13 07 2017 The present invention relates to a coating composition comprising a blend of a denatured protein, a lipid, a polyol plasticizer, trehalose, and a carrier. The invention further relates to methods of producing coating compositions, and products coated with the coating compositions. The invention further relates to use of a coating composition to mask, or reduce or prevent development of, flavours. Also, the present invention relates to use of a coating composition to prevent or reduce degradation of an active in a coated product, or to prevent or reduce leakage of an active from a coated product. Certain embodiments of the present invention relate to coating compositions that are suitable for coating microparticles. Some embodiments of the present invention relate to use of a coating composition to maintain probiotic viability or to improve probiotic survival in a product containing a probiotic.
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Dynamic interactions between tumor B cells and the tumor microenvironment (TME) are hypothesized to contribute to the broad spectrum of clinical behaviors observed among FL patients. Despite the urgent need, existing clinical tools do not reliably predict disease behavior. Using a multi-modal strategy, we examined cell-intrinsic and -extrinsic factors governing progression and therapeutic outcomes in FL patients enrolled onto a prospective clinical trial. By leveraging the strengths of each platform, we identify several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk FL patients. These features include stromal desmoplasia and changes to the follicular growth pattern present 20 months before first progression and first relapse.
PURPOSE: To obtain a low irritant bathing agent composition, containing an N-alkylamidealkanol sulfate ester salt, excellent in foaming properties and good in skin touch. CONSTITUTION: This bathing agent composition contains 0.1-90wt.% compound of the formula [R<1> is a 6-22C alkyl or alkenyl; R<2> is a 1-22C alkyl, alkenyl or H; R<3> is a 1-5C alkylene; R<4> O is a 2-3C oxyalkylene; (n) is 0-20; M is a cation] as an active ingredient. Furthermore, ingredients used in a usual bathing agent can suitably be blended therewith and prepared into a liquid, a pasty, a solid, a granular forms, etc. The bathing agent has neither squeakiness in bathing nor a tight feeling after the bathing. Thereby, a refreshing touch is obtained. Sodium salt of glycolic acid monolaurylamide sulfate ester is exemplified as the compound of the formula.
Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
Bronchopulmonary dysplasia is a chronic lung disease that affects a ratio of up to 20-30% of infants prematurely born before 30rd week. Delay of starting to speak, cerebral palsy and cognitive disorders may be seen in infants suffering from this disease. Although all the evidence found on the specific mediators and pathways that regulate the mechanism by studies made to understand the pathophysiologic mechanism, there hasn't been any remarkable progress on preventing the development of BPD in new-born infants born below 1500gr body weight. BPD is still one of the most important morbidity and mortality reasons in premature infants. There is a need of further studies to understand the genetic background of BPD specific to different populations, to identify polymorphisms related with the disease and for developing genetic methods for early the diagnose of the disease.

With this purpose, first of all polymorphisms related with BPD and those which are related with similar other lung diseases will be investigated. DNA samples derived from blood samples of 200 patients (100 BPD infant and 100 control) will be examined for polymorphisms in specific genes that are chosen in the light of the prior literature scanning. To the investigators' knowledge, this will be the first study of a broad scanning of polymorphisms related with BPD in Turkish population.
Eighteen subjects will be randomly assigned to receive either GR2001 or placebo at a 2:1 ratio (i.e. 12 subjects receive GR2001 and 6 with placebo) followed by a dose of Tetanus Toxoid（TT） on Day0.
The disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based composition comprising; vegetable derived glycerine and an emulsifier. The emulsifier can be any known and/or commercially available glucoside containing substance. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may be added to impart desirable mechanical and physio-chemical properties. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture. The composition includes glycerine preferably present in the range of 50-95 weight %.
Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
Cancer therapy-related cardiac dysfunction (CTRCD), which commonly includes left ventricular dysfunction and heart failure, is the main adverse effect of anticancer therapy. In recent years several candidate genes studies and genome-wide association studies have identified common genetic variants associated with CTRCD, but evidence remains limited and few genetic variants are robust. A genome-wide meta-analysis of CTRCD was performed with 852 oncology patients receiving cancer therapy. DNA samples were genotyped and imputed to perform a GWAS meta-analysis for case-control (N = 852 (380 cases and 472 controls) and extreme phenotypes (N = 618 (78 cases and 472 controls) looking for genetic variants that predispose to CTRCD. The results were validated in a replicate cohort of 1,191 oncology patients (245 cases and 946 controls). Functional mapping of the replicated loci was then performed. The meta-analysis showed 9 and 17 loci suggestively associated (P-value < 1 × 10-5) with CTRCD in case-control and extreme phenotypes analyses, respectively. The 3q28 locus (rs rs7652759, P = 5.64 × 10-6) in the case-control analysis was the strongest signal, with up to 64 SNPs above the suggestive significance threshold. The rs7652759, an intergenic variant between TPRG1 and TP63 genes, was the only variant validated in the replication cohort (P-value = 0.01). Functional mapping of this significant locus revealed up to 5 new genes potentially involved in the CTRCD. We identified the intergenic region near TP63 as a novel CTRCD susceptibility locus. In the future, the genotyping of these markers could be considered in new CTRCD risk scores to improve preventive strategies in cardio-oncology.
PROBLEM TO BE SOLVED: To obtain the subject composition having a high stability against light and heat by including a tea polyphenol and a specific salt of polyoxythylene alkylsulfosuccinate. SOLUTION: The objective composition comprises (A) a tea polyphenol and (B) a salt of polyoxythylene alky sulfosuccinate of the formula [R is C12 H25 or C14 H29 ; (n) is 1-5]; M is K or Na], (e.g. disodium polyoxyethylene alkyl sulfosuccinate). The tea means the leaves, stems, wooden parts, roots, seeds of Camellia sinensis and the mixture thereof. The kinds of the tea is any of a fermented tea such as black tea and a pu ehr tea, a semi-fermented tea such as oolong tea and a pouchung tea and unfermented tea such as green tea and roasted tea. (+)-Catechin, (-)-catechin, (+)-epigallocatechin gallate, free theaflavin or the like is cited as the component A.
Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
The present invention relates to polyethylene glycol modified protein medicaments. Disclosed are pegylated tissue kallikrein, a preparation method therefor, and uses thereof. The tissue kallikrein has a sequence shown in SEQ ID No. 1 or SEQ ID No. 2, the tissue kallikrein can be natural or recombinant, polyethylene glycol is polyethylene glycol with a molecular weight of 20-40kDa, and is coupled on an N-terminal primary amine of the tissue kallikrein. The pegylated KLK1 provided in the present invention has the advantages of significantly-extended life period, significantly-reduced immunogenicity and a stable and uniform structure, can be used for improving activities of the pegylated tissue kallikrein to a higher extent, and particularly, has more significant biological activities in the aspect of treating cerebral apoplexy and diabetic nephropathy.
AIDS-associated malignancy represents a model system for investigations of carcinogenesis. There are few human conditions in which cancer rates are of the magnitude they are in HIV infection. While studies have investigated pre-cancer markers in HIV-infected patients, they have not correlated these markers with tumor samples. This study contributes to understanding oncogenesis of HIV-associated malignancies by establishing a collection of tumors linked with pre-cancer sera and lymphocyte specimens, as well as prospective questionnaire data.

At study entry, patients receive a comprehensive physical exam. Clinic staff interview the patient to collect data regarding medication history (particularly antiretroviral exposure), diet, occupational history, substance abuse, and sexual practices. This information is used to identify behavioral and environmental factors contributing to oncogenesis. In addition, baseline blood samples are analyzed for HHV-8 and EBV levels, anti-EBV and anti-HHV-8 antibodies, CD23, Th2 cytokines, tumor growth factors, chromosomal translocations associated with NHL, and other potential predictors of malignancy. At Month 6 and annually thereafter, patient records are abstracted for data on vital status, AIDS-defining illnesses, medications, and most recent CD4+ T cell and HIV RNA levels. At Years 1, 2, and 3, patients undergo physical exams and blood tests for malignancy surveillance. Any malignancies are biopsied and analyzed for oncogene identification and virology. The medical records of patients who die on study are reviewed to determine the cause of death and to rule out unreported cancer. No treatment is provided by this study.
There are no studies of Tribenzor in patients with hepatic insufficiency, but both amlodipine and olmesartan medoxomil show moderate increases in exposure in patients with severe hepatic impairment. The recommended initial dose of amlodipine in patients with severe hepatic impairment is 2.5 mg, a dose not available with Tribenzor [see Warnings and Precautions (5.5)].

Amlodipine.Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t ½) is 56 hours in patients with severely impaired hepatic function. 

Olmesartan medoxomil.Increases in AUC 0-∞and peak plasma concentration (C max) for olmesartan were observed with moderate hepatic impairment compared to those in matched controls with an increase in AUC of about 60%. 

Hydrochlorothiazide. In patients with impaired hepatic function or progressive liver disease, minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Red light optogenetic systems are in high demand for the precise control of gene expression for gene- and cell-based therapies. Here, we report a red/far-red light-inducible photoswitch (REDLIP) system based on the chimeric photosensory protein FnBphP (Fn-REDLIP) or PnBphP (Pn-REDLIP) and their interaction partner LDB3, which enables efficient dynamic regulation of gene expression with a timescale of seconds without exogenous administration of a chromophore in mammals. We use the REDLIP system to establish the REDLIP-mediated CRISPR-dCas9 (REDLIPcas) system, enabling optogenetic activation of endogenous target genes in mammalian cells and mice. The REDLIP system is small enough to support packaging into adeno-associated viruses (AAVs), facilitating its therapeutic application. Demonstrating its capacity to treat metabolic diseases, we show that an AAV-delivered Fn-REDLIP system achieved optogenetic control of insulin expression to effectively lower blood glucose levels in type 1 diabetes model mice and control an anti-obesity therapeutic protein (thymic stromal lymphopoietin, TSLP) to reduce body weight in obesity model mice. REDLIP is a compact and sensitive optogenetic tool for reversible and non-invasive control that can facilitate basic biological and biomedical research.
Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue Butorphanol Tartrate Nasal Spray in a patient physically dependent on opioids. Rapid tapering of Butorphanol Tartrate Nasal Spray in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing Butorphanol Tartrate Nasal Spray, gradually taper the dosage using a patient-specific plan that considers the following: the dose of Butorphanol Tartrate Nasal Spray the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see DOSAGE AND ADMINISTRATION, and WARNINGS].

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Pregnancy].
PURPOSE: Detection and prediction of the rate of brain volume loss with age is a significant unmet need in patients with primary progressive multiple sclerosis (PPMS). In this study we construct detailed brain volume maps for PPMS patients. These maps compare age-related changes in both cortical and sub-cortical regions with those in healthy individuals.
METHODS: We conducted retrospective analyses of brain volume using T1-weighted Magnetic Resonance Imaging (MRI) scans of a large cohort of PPMS patients and healthy subjects. The volume of brain parenchyma (BP), cortex, white matter (WM), deep gray matter, thalamus, and cerebellum were measured using the robust SynthSeg segmentation tool. Age- and gender-related regression curves were constructed based on data from healthy subjects, with the 95% prediction interval adopted as the normality threshold for each brain region.
RESULTS: We analyzed 495 MRI scans from 169 PPMS patients, aged 20-79 years, alongside 563 exams from healthy subjects aged 20-86. Compared to healthy subjects, a higher proportion of PPMS patients showed lower than expected brain volumes in all regions except the cerebellum. The most affected areas were BP, WM, and thalamus. Lower brain volumes correlated with longer disease duration for BP and WM, and higher disability for BP, WM, cortex, and thalamus.
CONCLUSIONS: Constructing age- and gender-related brain volume maps enabled identifying PPMS patients at a higher risk of brain volume loss. Monitoring these high-risk patients may lead to better treatment decisions and improve patient outcomes.
1. A pharmaceutical composition for the treatment of cardiovascular diseases, which contains 3-(2,2,2-trimethylhydrazinum)propionate and γ-butyrobetaine as an active system and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition according to Claim 1, wherein the ratio of the mentioned substances inthe composition is within 1:10, preferably 1:3, to 3:1. 3. The pharmaceutical composition according to Claim 1 or 2, which is intended for oral or sublingual administration and is in the form of tablets (with or without coating), capsules, caplets, dragees, granules, powder or solution, which contain 0.01-0.5 g of the active system in every tablet, capsule, dragee, granule or powder dose, or also as a 0.5-40% solution or syrup for oral administration. 4. The pharmaceutical composition according to Claim 3, wherein pharmaceutically acceptable carrier is selected from the group consisting of stearinic acid and its salts, lactose, glucose, saccharose, starch, talc, vegetable oils, polyethylene glycols, microcrystalline cellulose, aerosil, aromatizers, flavoring agents, colorants, ethyl alcohol and water, which are taken separately or are used in combination. 5. The pharmaceutical composition according to Claim 1 or 2, wherein which is intended for parenteral administration and is in a solution form for injections, which contain 0.5-40% by weight of the active system and a pharmaceutically acceptable solvent. 6. The pharmaceutical composition according to Claim 5, wherein the pharmaceutically acceptable solvent is selected from the group consisting of distilled water, isotonic solution, buffer solution and glucose solution, which are taken separately or are used in combination. 7. The pharmaceutical composition according to Claim 1 or 2, which is intended for transcutaneous administration of the active system and in the form of ointment, solution or plaster, which contain 0.5-40% by weight of the active system and a pharmaceutically acceptable carrier. 8. The pharmaceutical composition according to Claim 7, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, polyethylene glycols 400, 1500 and 4000, vegetable oils, fats, glycerine, preservants, emulgators, stabilizers, porous polymer material, dimethyl-sulphoxide, alcohol and water, which are taken separately or are used in combination. 9. The pharmaceutical composition according to Claim 1 or 2, which is intended for rectal administration of the active system in the form of suppositories or microenema, which contain 0.5-40% by weight of the active system and a pharmaceutically acceptable carrier. 10. The pharmaceutical composition according to Claim 9, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, polyethylene glycols 400, 1500 and 4000, vegetable oils, fats, glycerine, preservants, emulgators, stabilizers, which are taken separately or are used in combination.
FUROSCIX is a sterile, clear to slightly yellow, non-pyrogenic liquid supplied in a single-dose prefilled cartridge for subcutaneous infusion co-packaged with the On-body Infusor. Each single-use On-body Infusor with prefilled cartridge is designed to deliver 80 mg of FUROSCIX in 10 mL solution over 5-hours.

Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature]. Do not refrigerate or freeze.

Protect FUROSCIX from light. Do not remove the cartridge from carton until it is ready for use. Do not use if the solution is discolored or cloudy. Protect the On-body Infusor from water.
Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
Patients receive clinical care consistent with current practice at NEVHC as described in Arm I. Patients also receive enhanced GI care coordination from GI liaisons, who generate GI FIT Tracker reports and use the GI FIT Tracker reports to follow patients with abnormal FIT results. Patients receive navigation services including contact from GI liaisons about making a GI appointment and enhanced communication between GI specialists and the NEVHC. Patients receive referral to gastroenterology following a standardized referral template and receive colonoscopy education including an informational sheet at the time of referral and a 20-minute pre-colonoscopy educational video. Patients receive a text message at the time of colonoscopy referral emphasizing the importance of colonoscopy after abnormal FIT result.